Kawaguchi Shinji, Soma Yusuke, Nakajima Kazuaki, Kanazawa Hideaki, Tohyama Shugo, Tabei Ryota, Hirano Akinori, Handa Noriko, Yamada Yoshitake, Okuda Shigeo, Hishikawa Shuji, Teratani Takumi, Kunita Satoshi, Kishino Yoshikazu, Okada Marina, Tanosaki Sho, Someya Shota, Morita Yuika, Tani Hidenori, Kawai Yujiro, Yamazaki Masataka, Ito Akira, Shibata Rei, Murohara Toyoaki, Tabata Yasuhiko, Kobayashi Eiji, Shimizu Hideyuki, Fukuda Keiichi, Fujita Jun
Department of Cardiovascular Surgery, Keio University School of Medicine, Tokyo, Japan.
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
JACC Basic Transl Sci. 2021 Feb 19;6(3):239-254. doi: 10.1016/j.jacbts.2020.11.017. eCollection 2021 Mar.
The severe shortage of donor hearts hampered the cardiac transplantation to patients with advanced heart failure. Therefore, cardiac regenerative therapies are eagerly awaited as a substitution. Human induced pluripotent stem cells (hiPSCs) are realistic cell source for regenerative cardiomyocytes. The hiPSC-derived cardiomyocytes are highly expected to help the recovery of heart. Avoidance of teratoma formation and large-scale culture of cardiomyocytes are definitely necessary for clinical setting. The combination of pure cardiac spheroids and gelatin hydrogel succeeded to recover reduced ejection fraction. The feasible transplantation strategy including transplantation device for regenerative cardiomyocytes are established in this study.
供体心脏的严重短缺阻碍了晚期心力衰竭患者的心脏移植。因此，人们急切期待心脏再生疗法作为替代方案。人诱导多能干细胞（hiPSC）是用于再生心肌细胞的现实细胞来源。hiPSC衍生的心肌细胞被寄予厚望，有望帮助心脏恢复。避免畸胎瘤形成以及大规模培养心肌细胞对于临床应用而言绝对必要。纯心脏球体与明胶水凝胶的组合成功恢复了降低的射血分数。本研究建立了包括用于再生心肌细胞的移植装置在内的可行移植策略。
